Camphene is a widely distributed bicyclic monoterpene found across conifer, rosemary, ginger, sage, frankincense, and other essential-oil profiles already represented in the AromaForge archive. Compared with many archive terpenes, it has a relatively substantial preclinical literature: live sources support its identity and multiple animal or cell-model studies around lipid metabolism, oxidative stress, and pain-related models. The evidence is still preclinical rather than clinical, so archive copy should present camphene as a research-active terpene with broad occurrence and moderate mechanistic interest, not as a validated medical ingredient.
Chemical identity and composition
PubChem and NIST identify camphene as C10H16 with CAS 79-92-5 and the bicyclic name 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane. The archive already uses camphene across many oils including ginger, rosemary, fir, pine, frankincense, and angelica root, reflecting its status as a common monoterpene marker rather than a rare specialty constituent.
Aroma and practical use
- Use the recorded camphoraceous, piney, woody, cooling descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2011 rat study reported that camphene lowered total cholesterol, LDL cholesterol, and triglycerides in detergent-induced hyperlipidemia without acting through HMG-CoA reductase inhibition.
The abstract reports about 54.5% lower total cholesterol, 54% lower LDL cholesterol, and 34.5% lower triglycerides at the tested dose in hyperlipidemic rats.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 high-fat-diet mouse study reported that dietary camphene attenuated hepatic steatosis and insulin resistance, with adiponectin-AMPK signaling proposed as a key pathway.
The paper supports a metabolism-focused constituent signal, but it remains an animal feeding study rather than a human metabolic trial.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2016 mechanistic study reported that camphene reduced cholesterol and triglyceride synthesis in HepG2-related experiments and proposed SREBP-1 and MTP modulation as part of its hypolipidemic action.
This is one of the clearer mechanism papers for isolated camphene, although it still relies on cell systems and interpretation of pathway markers.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2024 rat ex vivo myocardial ischemia-reperfusion study reported that camphene pretreatment reduced infarct size and cell-death markers while improving redox-related readouts.
The results add a newer cardioprotection signal, but the model is still preclinical and should not be translated into cardiovascular treatment claims.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2013 experimental-model paper found that (+)-camphene showed antioxidant effects in vitro and antinociceptive activity at high doses in mice.
The paper supports pain- and redox-related research interest, but the tested doses and model design keep the evidence at an exploratory stage.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
PubChem's summary describes camphene as a colorless to white crystalline material with an insipid camphor-like odor and notes that dust and crystals can irritate the eyes, nose, and throat.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No constituent-specific human clinical safety program or archive-ready IFRA exposure limit for isolated camphene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because most direct benefit papers are animal or cell-model studies, archive descriptions should avoid implying that the preclinical metabolic or cardioprotective findings are established in humans.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
alpha-PineneNeutral record
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
traditional · effect
No source citation attached.
Read alpha-Pinene report →LimoneneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Limonene report →How the effects were investigated
SREBP-1 and microsomal triglyceride transfer protein-linked lipid regulation
HepG2 and animal-model work suggests camphene alters cholesterol and triglyceride handling through SREBP-1 and MTP-related pathways rather than by directly inhibiting HMG-CoA reductase like a statin.
This experimental finding does not establish benefit, dose or safety in people using this blend.
adiponectin-AMPK signaling in hepatic steatosis model
A diet-induced mouse study linked camphene to increased adiponectin signaling, AMPK activation, greater fatty-acid-oxidation gene expression, and lower lipogenesis markers.
This experimental finding does not establish benefit, dose or safety in people using this blend.
redox-homeostasis support under oxidative or ischemia-reperfusion stress
Cell and ex vivo heart studies report lower lipid peroxidation and ROS-related injury together with shifts in antioxidant enzymes and related redox markers.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No high-quality human clinical trial of isolated camphene was verified in this pass.
- Many mechanistic claims come from one connected hypolipidemia literature thread and would benefit from broader independent replication.
- The RIFM 2023 safety assessment reports a weight-of-evidence NESIL of 7200 micrograms/cm2 (weak sensitizer) and no expected photoirritation/photoallergenicity, but no single finished-product dermal-limit percentage was located, so dermal_limit_pct was corrected from an unsourced placeholder to null rather than left as a guessed number.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.